Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
机构:[1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China[2]State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, China[3]KingMed Virology Diagnostic & Translational Center, Guangzhou, China[4]Technology Centre, Guangzhou Customs, Guangzhou, China[5]Kunming University of Science and Technology Library, Kunming, China[6]Jilin Yatai Chinese Medicine Development Institute, Changchun, Jilin, China
China Postdoctoral Science Foundation
(2020T130028ZX), Department of Education of Guangdong Provincial
(2020KZDZX1159), Science research project of the Guangdong
Province (Nos. 2020B111110001), Macao Science and Technology
Development Fund (0172/2019/A3), National Key R&D Program of
China (2020YFC0842400), Foshan Science and Technology Bureau
(2020001000206), China Evergrande Group, Jack Ma Foundation
(2020-CMKYGG-02), National Key Technology R&D Program
(2018YFC1311900) and Guangdong Science and Technology
Foundation (2019B030316028).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类|2 区医学
小类|1 区全科医学与补充医学2 区药物化学2 区药学2 区植物科学
最新[2025]版:
大类|1 区医学
小类|1 区药物化学1 区全科医学与补充医学1 区药学1 区植物科学
第一作者:
第一作者机构:[1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China[2]State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, China[3]KingMed Virology Diagnostic & Translational Center, Guangzhou, China
推荐引用方式(GB/T 7714):
Ma Qinhai,Li Runfeng,Pan Weiqi,et al.Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.[J].Phytomedicine : international journal of phytotherapy and phytopharmacology.2020,78:153296.doi:10.1016/j.phymed.2020.153296.
APA:
Ma Qinhai,Li Runfeng,Pan Weiqi,Huang Wenbo,Liu Bin...&Yang Zifeng.(2020).Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway..Phytomedicine : international journal of phytotherapy and phytopharmacology,78,
MLA:
Ma Qinhai,et al."Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.".Phytomedicine : international journal of phytotherapy and phytopharmacology 78.(2020):153296